During the past decade, Center for Arthritis and Rheumatic Diseases, PC conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 11 clinical trials were completed, i.e. on average, 122.2% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Center for Arthritis and Rheumatic Diseases, PC" #1 sponsor was "Pfizer" with 5 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored, "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 1 trials sponsored and "Regeneron Pharmaceuticals" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Arthritis and Rheumatic Diseases, PC" #1 collaborator was "Incyte Corporation" with 1 trials as a collaborator, "Laboratory Corporation of America" with 1 trials as a collaborator, "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator and "The Cleveland Clinic" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Center for Arthritis and Rheumatic Diseases, PC" are "Rheumatoid Arthritis" (7 trials), "Arthritis, Rheumatoid" (2 trials), "Osteoarthritis, Hip" (2 trials), "Osteoarthritis, Knee" (2 trials) and "Rheumatoid Arthritis (RA)" (2 trials). Many other conditions were trialed in "Center for Arthritis and Rheumatic Diseases, PC" in a lesser frequency.

Most popular intervention types in "Center for Arthritis and Rheumatic Diseases, PC" are "Drug" (10 trials), "Biological" (3 trials), "Other" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Adalimumab" (3 trials), "Baricitinib" (3 trials), "Methotrexate" (2 trials) and "Naproxen" (2 trials). Other intervention names were less common.

The vast majority of trials in "Center for Arthritis and Rheumatic Diseases, PC" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Center for Arthritis and Rheumatic Diseases, PC". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Center for Arthritis and Rheumatic Diseases, PC, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Center for Arthritis and Rheumatic Diseases, PC, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".